Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Ras Gene02:38

The Ras Gene

6.5K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.5K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

13.0K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
13.0K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

4.2K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.2K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Mutations01:39

Mutations

84.6K
Overview
84.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Site-specific differences in Nectin-4 expression and associated immune contexture in advanced urothelial carcinoma: implications for Nectin-4-targeted ADCs.

Therapeutic advances in medical oncology·2026
Same author

Targeting macrophage ferritin heavy chain mitigates ferroptosis and lung injury in experimental acute respiratory distress syndrome.

Nature communications·2026
Same author

FAP-1 loss impairs megakaryocyte demarcation membrane system and platelet function with myelofibrosis-like features.

Blood·2026
Same author

O-linked glycan-dependent gating of TPC2 controls lysosomal excitability and organelle remodeling.

Nature communications·2026
Same author

Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations.

Blood research·2026
Same author

Epigenetic reprogramming of T cell metabolism restores function and enhances anti-tumor immunity in lung cancer.

Nature immunology·2026

Related Experiment Video

Updated: Sep 17, 2025

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

7.7K

PHF6 and RUNX1 mutations cooperate to accelerate leukemogenesis.

Yueh-Chwen Hsu1, Chi-Yuan Yao2, Chang-Tsu Yuan3

  • 1Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Translational Oncology
|June 27, 2025
PubMed
Summary

Mutations in RUNX1 and PHF6 (plant homeodomain finger gene 6) synergistically drive acute myeloid leukemia (AML) development. This study reveals their joint pathological effects and identifies key molecular mechanisms, including Hmga2 upregulation in multipotent progenitors.

Keywords:
Acute myeloid leukemiaHmga2Leukemia stem cellPHF6, RUNX1

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.1K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

283

Related Experiment Videos

Last Updated: Sep 17, 2025

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

7.7K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.1K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

283

Area of Science:

  • Hematology
  • Molecular Biology
  • Cancer Genetics

Background:

  • RUNX1 is a key transcription factor in hematopoiesis, with mutations linked to hematological diseases.
  • PHF6, an epigenetic modifier, also has mutations associated with myeloid and lymphoid leukemia.
  • Previous research indicated a positive association between RUNX1 and PHF6 mutations, but their combined pathological effects were unknown.

Purpose of the Study:

  • To investigate the pathological basis of the association between RUNX1 and PHF6 mutations.
  • To analyze clinical, genetic, and transcriptomic features of acute myeloid leukemia (AML) patients with these mutations.
  • To explore the in vivo effects of combined RUNX1 and PHF6 mutations using a mouse model.

Main Methods:

  • Analysis of clinical, genetic, and transcriptomic data from 1188 adult AML patients.
  • Generation of a mouse model with combined RUNX1 and Phf6 mutations.
  • In vivo transplantation experiments using bone marrow cells from mutated mice.

Main Results:

  • A frequent co-occurrence of PHF6 and RUNX1 mutations was observed in AML patients, correlating with worse clinical outcomes.
  • Double-mutated cells showed enhanced leukemogenesis signatures and higher engraftment capacity in vivo, leading to shorter survival.
  • Multipotent progenitors (MPPs) were identified as the critical cell type, with upregulated Hmga2 contributing to self-renewal in double-mutated MPPs.

Conclusions:

  • RUNX1 and PHF6 mutations exhibit synergistic leukemogenic potential in vivo.
  • The study provides molecular insights into the pathogenesis of this high-risk AML subtype.
  • Upregulation of Hmga2 in MPPs is a key mechanism driving leukemogenesis in double-mutated AML.